← Leaderboards
Shweta Joshi
University Of California, San Diego
$2,465,663
Attributed
$2,465,663
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $560K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,465,663 · 2
By mechanism
R01$1,981,973 · 1
K22$483,690 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Diego
Same institution · by research overlap
- Mark Howard Ginsberg$41,669,148
- Atul Malhotra$26,152,466
- Eugene R Bleecker$21,321,746
- Kelan G Tantisira$14,938,349
- David Jay Reinkensmeyer$8,887,827
Others in their field
Other Emerging Leaders on “Inflammatory”
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$21,969,486
- Gary Fanger · Rise Therapeutics, Llc$20,823,569
- Gina Montealegre · Leidos Biomedical Research, Inc.$19,781,641
- Jeffrey Reich · Sparian Biosciences, Inc.$13,729,307
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
- James Dale Berry · Brigham And Women'S Hospital$11,004,714
Research focus
InflammatoryMonoclonal AntibodiesImmune Checkpoint InhibitorImmunotherapyMacrophageMolecularCombinatorialImmuneImmunologicsImmunosuppressionGeneticLaboratoriesMediatingFailureAdaptive ImmunityCheckpoint TherapyGenetic TranscriptionCd8-Positive T-LymphocytesAnti-Tumor Immune ResponseCytotoxic Cd8 T CellsCellsImmunooncologyAdaptive Immune ResponseMouse Model
Grant awards (8)
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma$398,787
R01 · FY2025 · NS · contact PI
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma$386,825
R01 · FY2024 · NS · contact PI
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma$398,787
R01 · FY2023 · NS · contact PI
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma$398,787
R01 · FY2022 · NS · contact PI
Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity$161,230
K22 · FY2022 · CA · contact PI
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma$398,787
R01 · FY2021 · NS · contact PI
Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity$161,230
K22 · FY2021 · CA · contact PI
Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity$161,230
K22 · FY2020 · CA · contact PI